Canada Antibody Drug Conjugates Market Size & Outlook

The antibody drug conjugates market in Canada is expected to reach a projected revenue of US$ 1,158.0 million by 2033. A compound annual growth rate of 11.5% is expected of Canada antibody drug conjugates market from 2025 to 2033.
Revenue, 2024 (US$M)
$407.3
Forecast, 2033 (US$M)
$1,158.0
CAGR, 2025 - 2033
11.5%
Report Coverage
Canada

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Canada antibody drug conjugates market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Canada antibody drug conjugates market highlights

  • The Canada antibody drug conjugates market generated a revenue of USD 407.3 million in 2024 and is expected to reach USD 1,158.0 million by 2033.
  • The Canada market is expected to grow at a CAGR of 12.3% from 2025 to 2033.
  • In terms of segment, breast cancer was the largest revenue generating application in 2024.
  • Urothelial Carcinoma is the most lucrative application segment registering the fastest growth during the forecast period.


Antibody drug conjugates market data book summary

Market revenue in 2024USD 407.3 million
Market revenue in 2033USD 1,158.0 million
Growth rate12.3% (CAGR from 2025 to 2033)
Largest segmentBreast cancer
Fastest growing segmentUrothelial Carcinoma
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationBreast Cancer, Blood Cancer, Urothelial Carcinoma, Ovarian Cancer
Key market players worldwidePfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA


Other key industry trends

  • In terms of revenue, Canada accounted for 3.3% of the global antibody drug conjugates market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In North America, U.S. antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2033.
  • Mexico is the fastest growing regional market in North America and is projected to reach USD 361.1 million by 2033.

Breast cancer was the largest segment with a revenue share of 40.95% in 2024. Horizon Databook has segmented the Canada antibody drug conjugates market based on breast cancer, blood cancer, urothelial carcinoma, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.


Canada is expected to witness significant growth over the forecast period, owing to factors such as high cancer prevalence and major research activities. Key antibody drug products, such as Kadcyla, Adcetris, & Mylotarg, have been available in the market and have been effectively used for the treatment of various cancers.

In September 2020, Polivy was approved by Canadian Health authorities for treatment of diffuse large B-cell lymphoma. Various other ADCs are currently under review or in clinical development. The approval for new ADCs is expected to drive the market over the forecast period.

As per the World Cancer Research Fund, Canada has one of the highest cancer prevalence in the world, with approximately 334 cases per 100,000 individuals. Cancers such as lung cancer comprised ~13% of all cancer cases in Canada in 2020.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Antibody Drug Conjugates Market Companies

Name Profile # Employees HQ Website
ADC Therapeutics SA View profile 274 Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 https://www.adctherapeutics.com
GlaxoSmithKline Consumer Healthcare (GSK CH India) View profile 1001-5000 Gurgaon, Haryana, India, Asia https://india-consumer.gsk.com/
Astellas Pharma Inc View profile 14484 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 http://www.astellas.com
Daiichi Sankyo Co Ltd View profile 17435 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 https://www.daiichisankyo.com
Takeda Pharmaceutical Co Ltd View profile 49095 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 https://www.takeda.com
Gilead Sciences Inc View profile 18000 333 Lakeside Drive, Foster, CA, United States, 94404 https://www.gilead.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com

Canada antibody drug conjugates market size, by application, 2021-2033 (US$M)

Canada Antibody Drug Conjugates Market Outlook Share, 2024 & 2033 (US$M)

Canada antibody drug conjugates market size, by application, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online